Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma